Microbot Medical (NASDAQ:MBOT) Coverage Initiated at B. Riley Financial

Equities research analysts at B. Riley Financial started coverage on shares of Microbot Medical (NASDAQ:MBOT) in a note issued to investors on Friday. The firm set a “buy” rating and a $4.00 price target on the biotechnology company’s stock. B. Riley Financial’s price objective indicates a potential upside of 169.36% from the company’s previous close.

Several other equities research analysts have also recently weighed in on MBOT. Loop Capital set a $4.00 price objective on shares of Microbot Medical in a research report on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research report on Wednesday, July 8th. Zacks Research cut shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. HC Wainwright reissued a “buy” rating on shares of Microbot Medical in a report on Wednesday, August 19th. Finally, Wall Street Zen cut shares of Microbot Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 5th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Microbot Medical has an average rating of “Hold” and a consensus target price of $6.38.

Microbot Medical Stock Performance

Microbot Medical stock traded up $0.03 on Friday, reaching $1.49. The company’s stock had a trading volume of 46,747 shares, compared to its average volume of 1,423,936. The business’s fifty day moving average price is $1.68 and its 200 day moving average price is $2.00. The company has a market cap of $99.75 million, a price-to-earnings ratio of -6.19 and a beta of 1.03. Microbot Medical has a twelve month low of $1.44 and a twelve month high of $4.19.

Microbot Medical (NASDAQ:MBOT) last announced its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. As a group, equities analysts forecast that Microbot Medical will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new stake in shares of Microbot Medical during the first quarter worth approximately $57,000. Geode Capital Management LLC grew its holdings in Microbot Medical by 24.7% during the 2nd quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company’s stock worth $996,000 after acquiring an additional 78,121 shares during the period. American Century Companies Inc. bought a new stake in shares of Microbot Medical during the 2nd quarter valued at $32,000. XTX Topco Ltd bought a new stake in shares of Microbot Medical during the 2nd quarter valued at $43,000. Finally, Envestnet Asset Management Inc. acquired a new position in shares of Microbot Medical in the 3rd quarter valued at $98,000. Institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.